A 35-year-old man with a 3-month history of chronic follicular conjunctivitis, mild mucoid discharge, and intermittent foreign body sensation presents to the clinic. Examination reveals tarsal conjunctival follicles, no preauricular lymphadenopathy, and normal cornea. Gram stain of discharge is negative. Giemsa stain shows intracytoplasmic inclusion bodies in epithelial cells. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** Chronic follicular conjunctivitis with intracytoplasmic inclusion bodies on Giemsa stain is diagnostic of **chlamydial conjunctivitis** (*Chlamydia trachomatis*). ## Pathognomonic Features | Feature | Chlamydial Conjunctivitis | Gonococcal Conjunctivitis | |---------|---------------------------|---------------------------| | **Onset** | Insidious (2–3 weeks) | Acute (1–3 days) | | **Discharge** | Mucoid, mild | Copious, purulent | | **Pain/Photophobia** | Minimal | Severe | | **Preauricular LAD** | Absent or mild | Absent | | **Gram stain** | Negative | Gram-negative diplococci | | **Giemsa/DIF** | Intracytoplasmic inclusions | Not applicable | | **Corneal risk** | Low (rare keratitis) | High (rapid perforation) | ## Why Systemic Therapy Is Required **High-Yield:** Unlike gonococcal disease, chlamydial conjunctivitis does **not** cause rapid corneal perforation. However, systemic therapy is still mandatory because: 1. *Chlamydia* is an intracellular pathogen; topical therapy alone cannot eradicate it 2. Chronic infection risks cicatricial changes (symblepharon, trichiasis) if untreated 3. Systemic therapy treats concurrent urethritis/cervicitis and prevents ascending infection 4. Single-dose azithromycin is highly effective and improves compliance ## Management Algorithm ```mermaid flowchart TD A[Chronic follicular conjunctivitis]:::outcome --> B{Giemsa/DIF positive?}:::decision B -->|Yes: Intracytoplasmic inclusions| C[Chlamydial conjunctivitis]:::outcome C --> D[Systemic azithromycin 1 g single dose]:::action D --> E[Add topical tetracycline ointment QID × 6 weeks]:::action E --> F[Partner notification and treatment]:::action F --> G[Follow-up at 2–4 weeks]:::action B -->|No| H[Consider viral or allergic etiology]:::outcome ``` ## Rationale for Correct Answer **Clinical Pearl:** Azithromycin 1 g single dose is the DOC for chlamydial conjunctivitis because: - Single-dose regimen achieves high intracellular concentrations - Treats concurrent urogenital chlamydia (70% of cases have urethritis/cervicitis) - Excellent compliance (one-time dosing) - Topical tetracycline ointment provides local coverage and prevents secondary bacterial infection **Mnemonic:** **CHLAMYDIA** = **C**yclones (intracytoplasmic inclusions) + **H**igh systemic need + **L**ow corneal risk + **A**zithromycin (DOC) + **M**ucoid discharge + **Y**ellow-orange inclusions (Giemsa) + **D**iagnosis confirmed by DIF/PCR + **I**ncluded in STI screening + **A**lways treat partner ## Associated Management - Contact tracing: sexual partners must be treated (azithromycin 1 g single dose) - Screening for concurrent STIs (gonorrhea, syphilis, HIV) - Avoid topical corticosteroids (risk of chronic infection and cicatricial changes) - Neonatal prophylaxis: erythromycin or tetracycline ointment at birth [cite:Khurana Textbook of Ophthalmology Ch 5]